Qilu Pharmaceuticals myeloma drug to nale amine "Chipyi" officially listed

multiple Myeloma (MM) is a malignant blood tumor in which plasma cells proliferate abnormally in the bone marrow, which occurs in middle-aged and elderly people, with typical symptoms such as bone pain, renal insufficiency, hypercalcemia, anemia and repeated infectionsrecently, thePharmaceutical(http://announced the launch of the first multiple myeloma (MM)drug(http://the companyDeveloped by the(http://of Celgene, the original drug was first approved by the u.SFDA(http://in 2005 to treat bone marrow hyperplasia syndrome (MDS), which was approved in 2006 in conjunction with Disemi Pine for second-line treatment of multiple myeloma;later expanded FDA approval for thetreatment of set cell lymphoma; in January 2013, the commodity name "Rui Fumei" officially imported in China, is currently the recommended first-line drug in the treatment guidelines for multiple myeloma In July 2017, The United States negotiated a nearly 60% reduction in the scope of Medicare 　　At the end of 017, the first generic drug of that amine capsule was approved for listing, the current domestic market has Qilu Pharmaceuticals, Beijing Shuangyi Pharmaceuticals, Zhengda Tianqing Pharmaceuticals 3 enterprises (http:// of the La amine capsule series approved production, Qilu Pharmaceutical's products (http:// according to the generic drug 4 type of application for listing, has passed the consistency evaluation, Beijing Shuangyu Pharmaceutical, Zhengda Tianqing Pharmaceutical products have been submitted according to the current stage of the product series